Investors seeking to outperform the market often focus on hand-picking stocks. Selecting the right ones has proven to be a key factor in boosting wealth.
The closing price of United Therapeutics Corp (NASDAQ: UTHR) was $300.43 for the day%, Down $-0.35% from the previous closing price of $301.5. In other words, the price has decreased by -$0.35 from its previous closing price. On the day, 0.58 million shares were traded. UTHR stock price reached its highest trading level at $306.0 during the session, while it also had its lowest trading level at $300.55.
Ratios:
Our analysis of UTHR’s different ratios will help us gain a deeper understanding of the company. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 4.46 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 12.72. For the most recent quarter (mrq), Quick Ratio is recorded 6.94 and its Current Ratio is at 7.26. In the meantime, Its Debt-to-Equity ratio is 0.00 whereas as Long-Term Debt/Eq ratio is at 0.00.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Cantor Fitzgerald on June 02, 2025, initiated with a Overweight rating and assigned the stock a target price of $405.
BofA Securities Upgraded its Underperform to Neutral on April 21, 2025, while the target price for the stock was maintained at $314.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Aug 07 ’25 when MAHON PAUL A sold 11,000 shares for $300.00 per share. The transaction valued at 3,299,981 led to the insider holds 36,781 shares of the business.
PAUL MAHON bought 11,000 shares of UTHR for $3,299,980 on Aug 07 ’25. On Jul 24 ’25, another insider, MAHON PAUL A, who serves as the EVP & GENERAL COUNSEL of the company, sold 11,000 shares for $304.11 each. As a result, the insider received 3,345,225 and left with 36,781 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, UTHR now has a Market Capitalization of 13587337216 and an Enterprise Value of 10538626048. As of this moment, United’s Price-to-Earnings (P/E) ratio for their current fiscal year is 11.73, and their Forward P/E ratio for the next fiscal year is 10.41. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 2.62. For the stock, the TTM Price-to-Sale (P/S) ratio is 4.41 while its Price-to-Book (P/B) ratio in mrq is 1.89. Its current Enterprise Value per Revenue stands at 3.424 whereas that against EBITDA is 6.599.
Stock Price History:
The Beta on a monthly basis for UTHR is 0.61, which has changed by -0.071572065 over the last 52 weeks, in comparison to a change of 0.17279088 over the same period for the S&P500. Over the past 52 weeks, UTHR has reached a high of $417.82, while it has fallen to a 52-week low of $266.98. The 50-Day Moving Average of the stock is 1.05%, while the 200-Day Moving Average is calculated to be -8.71%.
Shares Statistics:
UTHR traded an average of 599.62K shares per day over the past three months and 893840 shares per day over the past ten days. A total of 45.22M shares are outstanding, with a floating share count of 44.08M. Insiders hold about 2.53% of the company’s shares, while institutions hold 99.20% stake in the company. Shares short for UTHR as of 1752537600 were 1600574 with a Short Ratio of 2.67, compared to 1749772800 on 1614964. Therefore, it implies a Short% of Shares Outstanding of 1600574 and a Short% of Float of 4.65.
Earnings Estimates
The dynamic stock of United Therapeutics Corp (UTHR) is currently attracting attention from 11.0 analysts actively involved in rating its market status.The consensus estimate for the next quarter is $6.52, with high estimates of $7.57 and low estimates of $4.83.
Analysts are recommending an EPS of between $28.09 and $25.03 for the fiscal current year, implying an average EPS of $26.96. EPS for the following year is $27.7, with 12.0 analysts recommending between $31.03 and $23.5.
Revenue Estimates
It is expected that $90B in revenue will be generated in the current quarter, according to 10 analysts. It ranges from a high estimate of $936M to a low estimate of $792.6M. As of the current estimate, United Therapeutics Corp’s year-ago sales were $748.9MFor the next quarter, 10 analysts are estimating revenue of $809.03M. There is a high estimate of $844M for the next quarter, whereas the lowest estimate is $771.3M.
A total of 13 analysts have provided revenue estimates for UTHR’s current fiscal year. The highest revenue estimate was $3.3B, while the lowest revenue estimate was $3.13B, resulting in an average revenue estimate of $3.22B. In the same quarter a year ago, actual revenue was $2.88BBased on 13 analysts’ estimates, the company’s revenue will be $3.4B in the next fiscal year. The high estimate is $3.6B and the low estimate is $3.07B.
